Annals of Nuclear Medicine

, Volume 27, Issue 7, pp 581–591

Choline PET/CT for imaging prostate cancer: an update

  • Kazuhiro Kitajima
  • Robert C. Murphy
  • Mark A. Nathan
Review Article

DOI: 10.1007/s12149-013-0731-7

Cite this article as:
Kitajima, K., Murphy, R.C. & Nathan, M.A. Ann Nucl Med (2013) 27: 581. doi:10.1007/s12149-013-0731-7

Abstract

Whole-body positron emission tomography/computed tomography (PET/CT) with [11C]- and [18F]-labeled choline derivates has emerged as a promising molecular imaging modality for the evaluation of prostate cancer. 11C- and 18F-choline PET/CT are used successfully for restaging prostate cancer in patients with biochemical recurrence of disease after definitive therapy, especially when the serum prostate-specific antigen level is >1.0 ng/mL. 11C- and 18F-choline PET/CT have more limited roles for the initial staging of prostate cancer and for the detection of tiny lymph node metastases due to the low spatial resolution inherent to PET. Overall, these modalities are most useful in patients with a high pre-test suspicion of metastatic disease. The following is a review of the current clinical roles of 11C- and 18F-choline PET/CT in the management of prostate cancer.

Keywords

Prostate cancer Staging Restaging 11C-choline 18F-fluorocholine Positron emission tomography/computed tomography (PET/CT) 

Copyright information

© The Japanese Society of Nuclear Medicine 2013

Authors and Affiliations

  • Kazuhiro Kitajima
    • 1
  • Robert C. Murphy
    • 2
  • Mark A. Nathan
    • 2
  1. 1.Department of RadiologyKobe University Graduate School of MedicineKobeJapan
  2. 2.Department of RadiologyMayo ClinicRochesterUSA

Personalised recommendations